
The episode discusses the evolution of cannabis as medicine and the scientific advancements that support its use.
The cannabis industry convinced the world it had a medicine before the science caught up. Now the science is here, and almost no one is paying attention. CBD is not a panacea. When Charlotte's Web opened hearts and minds, the messaging of what it could do ran years ahead of what the data could actually support. That gap created a backlash the legitimate medical thesis didn't deserve. What's left on the other side of the green rush is a near-complete forgetting of the reason this industry started in the first place. The medicine. Now the infrastructure to prove it is finally in place. Standardized genetics. Reproducible extraction. Full compound characterization. An FDA botanical drug pathway that has existed since 2016 that most investors have never heard of. Organic medicine versus synthetic single-molecule will be a real choice at the pharmacy counter sooner than most people expect. The foundational work is already here. This week we sit down with Joel Stanley and Dr. Marcel Bonn-Miller: Botanical drugs vs. supplements 6,000 compounds, one drug Novel compounds nobody has named yet
Host: Bryan Fields
Guests: Joel Stanley, Dr. Marcel Bonn-Miller
Organizations: Charlotte's Web, FDA
Explore listener stats, chart rankings, contacts and more on the The Dime podcast page.